A look through the new therapeutic window: irbesartan

Détails

ID Serval
serval:BIB_14C112AD8516
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
A look through the new therapeutic window: irbesartan
Périodique
Journal of Hypertension. Supplement
Auteur(s)
Waeber B., Brunner  H. R.
ISSN
0952-1178
Statut éditorial
Publié
Date de publication
1998
Volume
16
Numéro
7
Pages
S11-6
Langue
anglais
Notes
Comparative Study
Journal Article
Review
Résumé
Although an impressive array of efficacious antihypertensive agents are available to treat hypertension, the optimal use of these agents is limited by dose-related side-effect profiles. This is particularly the case for widely used first-line antihypertensive agents such as diuretics, beta-blockers, calcium antagonists, and alpha1-blockers; this represents a major therapeutic dilemma in treating hypertension. With the development of the angiotensin II receptor antagonists (AIIRAs), this dilemma might have been solved. Irbesartan is a long-acting AIIRA that provides dose-related efficacy with placebo-like tolerability at all clinical doses. The results of placebo and active-control trials of irbesartan have demonstrated that the agent is as effective as the leading members of major antihypertensive classes with respect to blood pressure control, while having superior tolerability. Pooled data from nine multicenter, randomized, placebo-controlled trials with irbesartan have documented no adverse events caused by dose-response. This feature could widen the traditionally narrow therapeutic window in the treatment of hypertension and point to the use of AIIRAs such as irbesartan as first-line therapy in the management of hypertension.
Mots-clé
Antihypertensive Agents/adverse effects/pharmacokinetics/*therapeutic useBiphenyl Compounds/adverse effects/pharmacokinetics/*therapeutic useBlood Pressure/drug effectsControlled Clinical Trials as TopicDose-Response Relationship, DrugFollow-Up StudiesHumansHypertension/*drug therapy/physiopathologyReceptors, Angiotensin/antagonists & inhibitorsSafetyTetrazoles/adverse effects/pharmacokinetics/*therapeutic useTreatment Outcome
Pubmed
Web of science
Création de la notice
06/03/2009 13:00
Dernière modification de la notice
20/08/2019 13:43
Données d'usage